Innate Pharma Delivers Strong Progress in FY 2025 Earnings Call, Sets Stage for Future Growth
In a highly anticipated earnings call, Innate Pharma's leadership team delivered a comprehensive update on the company's full-year 2025 performance and strategic priorities. The Q4 2025 conference call provided valuable insights into the company's progress across its core programs and its ambitious plans to drive growth in FY 2026.
Jonathan Dickinson, CEO of Innate Pharma, kicked off the presentation with a clear overview of the company's strategic vision and outlook. He emphasized the company's focus on delivering high-value differentiated therapies for patients with significant unmet medical need through its expertise in antibody engineering and innovation in immuno-oncology and antibody-drug conjugates (ADCs).
As highlighted by Dickinson, Innate Pharma has prioritized investment in three core clinical assets: IPH4502, lacutamab, and monalizumab. This strategic focus enables the company to concentrate resources where it sees the greatest potential for clinical impact and long-term value creation.
The call also provided a detailed update on the progress of these critical programs. Lacutamab, an antibody-drug conjugate (ADC), has received FDA clearance to proceed with the TELLOMAK 3 phase III trial in cutaneous T-cell lymphoma (CTCL). The company expects to initiate this trial in the second half of 2026.
IPH4502, a novel Nectin-4 ADC, is progressing rapidly, demonstrating early signs of antitumor activity in heavily pretreated patients, including those with urothelial cancer previously treated with EV. A favorable safety profile has been observed to date, and the company is validating its preclinical hypothesis supporting a differentiated profile compared to MMAE-based approaches.
Monalizumab, in partnership with AstraZeneca, represents another key late-stage asset with a phase III trial data readout expected in the second half of 2026. The PACIFIC-9 study will provide valuable insights into its efficacy and potential for future development.
Innate Pharma's leadership emphasized its commitment to driving value through prioritization of key milestones, efficient decision-making, and disciplined capital allocation. As stated by Dickinson, the company is well-positioned to deliver multiple catalysts over the near and medium term.
